Trial Profile
Trial of Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome (BCNS)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Vismodegib (Primary) ; Ipilimumab
- Indications Basal cell nevus syndrome
- Focus Therapeutic Use
- 16 Dec 2019 Planned initiation date changed from 1 Jun 2019 to 1 Jul 2019.
- 16 Dec 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 05 Apr 2019 Planned initiation date changed from 1 Feb 2019 to 1 Jun 2019.